Analysts’ Weekly Ratings Changes for Edgewise Therapeutics (EWTX)

A number of firms have modified their ratings and price targets on shares of Edgewise Therapeutics (NASDAQ: EWTX) recently:

• 6/17/2026 – Edgewise Therapeutics had its price target raised by Royal Bank Of Canada from $48.00 to $59.00. They now have an “outperform” rating on the stock.
• 6/17/2026 – Edgewise Therapeutics had its price target raised by The Goldman Sachs Group, Inc. from $20.00 to $32.00. They now have a “neutral” rating on the stock.
• 6/16/2026 – Edgewise Therapeutics was given a new $52.00 price target by Leerink Partners.
• 6/16/2026 – Edgewise Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $45.00 price target on the stock.
• 6/2/2026 – Edgewise Therapeutics had its price target lowered by Royal Bank Of Canada from $50.00 to $48.00. They now have an “outperform” rating on the stock.
• 6/2/2026 – Edgewise Therapeutics had its price target raised by HC Wainwright from $42.00 to $45.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Edgewise Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $66.00 price target on the stock.
• 6/1/2026 – Edgewise Therapeutics had its price target raised by Wedbush from $46.00 to $52.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – Edgewise Therapeutics was given a new $52.00 price target by Truist Financial Corporation.

Insiders Place Their Bets

In other Edgewise Therapeutics news, CMO Joanne M. Donovan sold 50,000 shares of Edgewise Therapeutics stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $38.57, for a total value of $1,928,500.00. Following the transaction, the chief marketing officer owned 4,367 shares in the company, valued at $168,435.19. The trade was a 91.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 83,892 shares of company stock valued at $3,018,216 over the last quarter. Company insiders own 21.30% of the company’s stock.

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.